Leishmaniasis Treatment Market Analysis, By Disease Type, By Pathological Tests, By Therapy Type, By End User, Forecast to 2027

Increasing global prevalence of leishmaniasis, and rising need for appropriate treatment are key factors driving market revenue growth.

Market Size - USD 124.4 Million in 2020, Market Growth - CAGR of 8.4%, Market Trends - Constant focus on R&D of advanced and novel treatment and increasing government support.

The global leishmaniasis treatment market size is expected to reach USD 237.7 Million in 2028, and register a CAGR of 8.4% during the forecast period. According to the data of 2017, the World Health Organization (WHO) has stated that leishmaniasis is one of the most neglected diseases, with 350 million people considered at risk of contracting the disease, with a burden of about 12 million people currently infected in 98 countries, and two million new cases estimated to occur annually.

According to the WHO reports, on average, an estimated 7 lakh to 1 million new cases arise every year, and some 26 000 to 65 000 deaths occur annually. The rising prevalence of the target disease is expected to boost market growth.

High prevalence of the diseases in rural and developing countries, increasing prevalence of malnutrition globally, lack of hygiene and poor sanitation facilities, migratory patterns of population, introduction of new chemical entity in the field of therapeutics, favorable government regulations, and increased R&D investments are major factors expected to drive growth of the global leishmaniasis treatment market to significant extent.

Some Key Findings From the Report:

Among the disease type segments, the visceral leishmaniasis segment accounted for the largest revenue share of 48.4% in 2020.
The Asia Pacific market size was USD 26.1 Million, due to increasing prevalence of the disease and rising need to treat patients suffering from this disease.
Key players profiled in the report include Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Profounda, Inc., Gland Pharma Limited, Gilead Life sciences, and Lifecare Innovations Private Limited. The market players have adopted various strategies including mergers, acquisitions, partnerships, and new product developments, among other strategies, to stay ahead of the competition and expand market footprint.
In 2020, Novartis International AG collaborated with a non-profit research and development organization - Drugs for Neglected Diseases initiative (DNDi) to develop a product, LXE408, intended to treat visceral leishmaniasis.

For the purpose of this report, the global Leishmaniasis treatment market is segmented on the basis of disease type, pathological test, therapy type, end-use, and region:

Disease Type Outlook

Cutaneous Leishmaniasis
Diffuse Cutaneous Leishmaniasis
Mucocutaneous Leishmaniasis
Mucosal Leishmaniasis
Visceral Leishmaniasis

Pathological Test Outlook

Serological Tests
Direct Agglutination Test
Indirect Immunofluorescent Antibody test (IFAT)
Enzyme-Linked Immunosorbent Assay (ELISA)
Others
Parasitological Evaluation
Punch Biopsy
Bone Marrow Biopsy
Others
DNA- Based Methods
Nucleic Acid Hybridization
Polymerase Chain Reaction (PCR)
Immunological Methods
Others

Therapy Type Outlook

Drug Therapy
Pentavalent Antimonials

 Sodium Stibogluconate

 SSG Meglumine antimoniate

Antifungal
Antibiotics

 Amphotericin B

 Liposomal amphotericin B

 Miltefosine

 Paromomycin

 Pentamidine

Non-Drug Therapy
Cauterization
Surgical Excision
Cryotherapy

End-Use Outlook

Hospitals
Clinics
Diagnostic Laboratories
Others

Region Outlook

North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Benelux
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of Asia Pacific
Latin America
Brazil
Rest of Latin America
Middle East and Africa
Saudi Arabia
UAE
South Africa
Rest of Middle East & Africa

Reasons to Buy the Report

A robust analysis and estimation of the Leishmaniasis Treatment Market with four levels of quality check - in-house database, expert interviews, governmental regulation, and a forecast specifically done through time series analysis
A holistic competitive landscape of the all the major players in the Leishmaniasis Treatment Market. The report covers their market shares, strategic initiatives, new product launches, R&D expenditure, M&As, Joint ventures, expansionary plans, product wise metric space analysis and key developments
Go-to-market strategies specifically formulated in line with location analysis which takes into the factors such as government regulations, supplier mapping, supply chain obstacles, and feedback from local vendors
Most deep dive segmental bifurcation available currently in the market. Our stellar methodology helps us understand the overall gamut of the supply chain and will help you explain the current market dynamics
Special focus given on vendor landscape, supplier portfolio, customer mapping, production capacity, and yearly capacity utilization

Chapter 1. Market Synopsis

1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique

Chapter 2. Executive Summary

2.1. Summary Snapshot, 2018 – 2026

Chapter 3. Indicative Metrics

3.1. Rising incidence of target infectious diseases
3.2. Growing awareness among patients and heathcare providers
3.3. Advance R&D facilities and new product developments by companies
3.4. Favorable Funding Scenario

Chapter 4. Leishmaniasis Treatment Market Segmentation & Impact Analysis

4.1. Leishmaniasis Treatment Segmentation Analysis
4.2. Leishmaniasis Treatment Market Value Chain Analysis, 2016-2026
4.3. Regulatory framework
4.4. Leishmaniasis Treatment Market Impact Analysis
4.4.1. Market driver analysis
4.4.1.1. Favorable Government Initiatives
4.4.1.2. New development in therapy area by key players
4.4.1.3. Increased R&D funding by agencies
4.4.2. Market restraint analysis
4.4.2.1. Long Duration of treatment
4.4.2.2. Lack Of Awareness In Developing Countries
4.5. Key opportunities prioritized
4.6. Leishmaniasis Treatment Pricing Analysis
4.7. Industry analysis - Porter's
4.8. Leishmaniasis Treatment Diagnostics PESTEL Analysis

Chapter 5. Leishmaniasis Treatment Market By Disease Type Insights & Trends

5.1. Leishmaniasis Treatment Disease Type dynamics & Market Share, 2018 & 2026
5.2. Cutaneous Leishmaniasis
5.2.1. Market estimates and forecast, 2016 – 2026 (USD Million)
5.2.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
5.2.3. Diffuse Cutaneous Leishmaniasis
5.2.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
5.2.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
5.2.4. Mucocutaneous Leishmaniais
5.2.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
5.2.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
5.3. Mucosal Leishmaniasis
5.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
5.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
5.4. Visceral Leishmaniasis
5.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
5.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)

Chapter 6. Leishmaniasis Treatment Market By Pathological Tests Insights & Trends

6.1. Leishmaniasis Treatment Pathological Tests dynamics & Market Share, 2018 & 2026
6.2. By Serological Tests
6.2.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.2.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.2.3. Direct Agglutination Test
6.2.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.2.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.2.4. Indirect Immunofluorescent Antibody test (IFAT)
6.2.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.2.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.2.5. Enzyme Linked Immunosorbent Assay (ELISA)
6.2.5.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.2.5.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.2.6. Others Market estimates and forecast, 2016 – 2026 (USD Million)
6.2.6.1. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.3. Parasitological Evaluation
6.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.3.3. Punch Biopsy
6.3.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.3.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.3.4. Bone Marrow Biopsy
6.3.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.3.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.3.5. Others
6.3.5.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.3.5.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.4. DNA- Based Methods
6.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.4.3. Nucleic Acid Hybridization
6.4.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.4.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.4.4. Polymerase Chain Reaction (PCR)
6.4.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.4.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.5. Immunological Methods
6.5.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.5.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
6.6. Others
6.6.1. Market estimates and forecast, 2016 – 2026 (USD Million)
6.6.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)

Chapter 7. Leishmaniasis Treatment Market By Therapy Type Insights & Trends

7.1. Leishmaniasis Treatment Therapy Type dynamics & Market Share, 2018 & 2026
7.2. By Drug Therapy
7.2.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.2.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.2.3. Pentavalent Antimonials
7.2.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.2.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.2.3.3. Sodium Stibogluconate
7.2.3.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.2.3.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.2.3.4. SSG Meglumine antimoniate
7.2.3.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.2.3.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.3. Antifungal
7.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.4. Antibiotics
7.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.4.3. Amphotericin B
7.4.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.4.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.4.4. Liposomal amphotericin B
7.4.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.4.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.4.5. Miltefosine
7.4.5.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.4.5.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.4.6. Paromomycin
7.4.6.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.4.6.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.4.7. Pentamidine
7.4.7.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.4.7.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.5. By Non-Drug Therapy
7.5.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.5.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.5.3. Cauterization
7.5.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.5.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.5.4. Surgical Excision
7.5.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.5.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
7.5.5. Cryotherapy
7.5.5.1. Market estimates and forecast, 2016 – 2026 (USD Million)
7.5.5.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)

Chapter 8. Leishmaniasis Treatment Market By End Use Insights & Trends

8.1. Leishmaniasis Treatment End Use dynamics & Market Share, 2018 & 2026
8.1.1. Market estimates and forecast, 2016 – 2026 (USD Million)
8.1.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
8.2. Hospitals
8.2.1. Market estimates and forecast, 2016 – 2026 (USD Million)
8.2.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
8.3. Clinics
8.3.1. Market estimates and forecast, 2016 – 2026 (USD Million)
8.3.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
8.4. Diagnostic Centers
8.4.1. Market estimates and forecast, 2016 – 2026 (USD Million)
8.4.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)
8.5. Others
8.5.1. Market estimates and forecast, 2016 – 2026 (USD Million)
8.5.2. Market estimates and forecast, by region, 2016 – 2026 (USD Million)

Chapter 9. Leishmaniasis Treatment Market Regional Outlook

9.1. Leishmaniasis Treatment Market share by region, 2018 & 2026
9.2. North America
9.2.1. North America Leishmaniasis Treatment Market estimates and forecast, 2016 – 2026, (USD Million)
9.2.2. North America Leishmaniasis Treatment Market estimates and forecast Disease Type, 2016 – 2026, (USD Million)
9.2.3. North America Leishmaniasis Treatment Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.2.4. North America Leishmaniasis Treatment Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.2.5. North America Leishmaniasis Treatment Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.2.6. U.S.
9.2.6.1. U.S. Leishmaniasis Treatment Market estimates and forecast, 2016 – 2026, (USD Million)
9.2.6.2. U.S. Leishmaniasis Treatment Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.2.6.3. U.S. Leishmaniasis Treatment Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.2.6.4. U.S. Leishmaniasis Treatment Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.2.6.5. U.S. Leishmaniasis Treatment Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.2.7. Canada
9.2.7.1. Canada Leishmaniasis Treatment Market estimates and forecast, 2016 – 2026, (USD Million)
9.2.7.2. Canada Leishmaniasis Treatment Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.2.7.3. Canada Leishmaniasis Treatment Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.2.7.4. Canada Leishmaniasis Treatment Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.2.7.5. Canada Leishmaniasis Treatment Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.3. Europe
9.3.1. Europe Leishmaniasis Treatment Market estimates and forecast, 2016 – 2026, (USD Million)
9.3.2. Europe Leishmaniasis Treatment Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.3.3. Europe Leishmaniasis Treatment Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.3.4. Europe Leishmaniasis Treatment Market estimates and forecast by therapy type , 2016 – 2026, (USD Million)
9.3.5. Europe Leishmaniasis Treatment Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.3.6. Germany
9.3.6.1. Germany Leishmaniasis Treatment Market estimates and forecast, 2016 – 2026, (USD Million)
9.3.6.2. Germany Leishmaniasis Treatment Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.3.6.3. Germany Leishmaniasis Treatment Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.3.6.4. Germany Leishmaniasis Treatment Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.3.6.5. Germany Leishmaniasis Treatment Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.3.7. France
9.3.7.1. France Leishmaniasis Treatment Market estimates and forecast, 2016 – 2026, (USD Million)
9.3.7.2. France Leishmaniasis Treatment Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.3.7.3. France Leishmaniasis Treatment Market estimates and forecast by Pathological Testing , 2016 – 2026, (USD Million)
9.3.7.4. France Leishmaniasis Treatment Market estimates and forecast by Therapy Type, 2016 – 2026, (USD Million)
9.3.7.5. France Leishmaniasis Treatment Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.3.8. U.K.
9.3.8.1. U.K Leishmaniasis Treatment Market estimates and forecast, 2016 – 2026, (USD Million)
9.3.8.2. U.K Leishmaniasis Treatment Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.3.8.3. U.K. Leishmaniasis Treatment Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.3.8.4. U.K. Leishmaniasis Treatment Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.3.8.5. U.K. Leishmaniasis Treatment Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.3.9. Spain
9.3.9.1. Spain Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.3.9.2. Spain Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.3.9.3. Spain Leishmaniasis Treatments Market estimates and forecast by Pathological Tests, 2016 – 2026, (USD Million)
9.3.9.4. Spain Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.3.9.5. Spain. Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.3.10. Italy
9.3.10.1. Italy Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.3.10.2. Italy Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.3.10.3. Italy Leishmaniasis Treatments Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.3.10.4. Italy Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.3.10.5. Italy Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.3.11. Rest of Europe
9.3.11.1. Rest of Europe Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.3.11.2. Rest of Europe Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.3.11.3. Rest of Europe Leishmaniasis Treatments Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.3.11.4. Rest of Europe Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.3.11.5. Rest of Europe Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.4.2. Asia Pacific Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.4.3. Asia Pacific Leishmaniasis Treatments Market estimates and forecast by Pathological Tests, 2016 – 2026, (USD Million)
9.4.4. Asia Pacific Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.4.5. Asia Pacific Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.4.6. China
9.4.6.1. China Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.4.6.2. China Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.4.6.3. China Leishmaniasis Treatments Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.4.6.4. China Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.4.6.5. China Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.4.7. Japan
9.4.7.1. Japan Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.4.7.2. Japan Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.4.7.3. Japan Leishmaniasis Treatments Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.4.7.4. Japan Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.4.7.5. Japan Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.4.8. India
9.4.8.1. India Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.4.8.2. India Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.4.8.3. India Leishmaniasis Treatments Market estimates and forecast by Pathological Test , 2016 – 2026, (USD Million)
9.4.8.4. India Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.4.8.5. India Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.4.9. Rest of Asia Pacific
9.4.9.1. Rest of Asia Pacific Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.4.9.2. Rest of Asia Pacific Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.4.9.3. Rest of Asia Pacific Leishmaniasis Treatments Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.4.9.4. Rest of Asia Pacific Leishmaniasis Treatments Market estimates and forecast by Therapy type , 2016 – 2026, (USD Million)
9.4.9.5. Rest of Asia Pacific Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.5. Middle East & Africa
9.5.1. Middle East and Africa Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.5.2. Middle East and Africa Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.5.3. Middle East and Africa Leishmaniasis Treatments Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.5.4. Middle East and Africa Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.5.5. Middle East and Africa Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.6. Latin America
9.6.1. Latin America Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.6.2. Latin America Leishmaniasis Treatments Market estimates and forecast by Diesease Type, 2016 – 2026, (USD Million)
9.6.3. Latin America Leishmaniasis Treatments Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.6.4. Latin America Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.6.5. Latin America Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)
9.6.6. Brazil
9.6.6.1. Brazil Leishmaniasis Treatments Market estimates and forecast, 2016 – 2026, (USD Million)
9.6.6.2. Brazil Leishmaniasis Treatments Market estimates and forecast by Disease Type, 2016 – 2026, (USD Million)
9.6.6.3. Brazil Leishmaniasis Treatments Market estimates and forecast by Pathological Tests , 2016 – 2026, (USD Million)
9.6.6.4. Brazil Leishmaniasis Treatments Market estimates and forecast by Therapy Type , 2016 – 2026, (USD Million)
9.6.6.5. Brazil Leishmaniasis Treatments Market estimates and forecast by End Use, 2016 – 2026, (USD Million)

Chapter 10. Competitive Landscape

10.1. Market Revenue Share by Manufacturers
10.2. Manufacturing Cost Breakdown Analysis
10.3. Mergers & Acquisitions
10.4. Strategy Benchmarking
10.5. Vendor Landscape

Chapter 11. Company Profiles

11.1. Sanofi S.A.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Length Benchmarking
11.1.4. Strategic Initiatives
11.2. Sequus Pharmaceuticals Inc
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Length Benchmarking
11.2.4. Strategic Initiatives
11.3. Paladin Labs Inc
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Length Benchmarking
11.3.4. Strategic Initiatives
11.4. Enzon Pharmaceuticals Inc
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Length Benchmarking
11.4.4. Strategic Initiatives
11.5. Gland Pharma Limited
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Length Benchmarking
11.5.4. Strategic Initiatives
11.6. Gilead Life sciences
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Length Benchmarking
11.6.4. Strategic Initiatives
11.7. Lifecare Innovations Private Limited
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Length Benchmarking
11.7.4. Strategic Initiatives